• 정신신체의학
• /
• 제17권1호
• /
• pp.30-36
• /
• 2009

연구목적 : 갑상선기능은 기분, 인지기능, 불안, 수면 등의 증상과 관련된다. 갑상선기능이상 시에 정신분열병 환자에서 음성증상, 기분, 신체증상에 어떤 차이가 있는지, 또 각각의 증상 변화와 어떻게 연관되는지를 연구하였다. 방법 : 정신분열병으로 입원했던 환자 65명을 입원 당시의 갑상선호르몬 수치에 따라 갑상선기능불안정 군과 갑상선기능정상 군으로 나누었다. 두 군의 입원 당시와 8주 후에 평가했던 음성증상평가척도(Scale for the Assessment of Negative Symptoms ; 이하 SANS), 양성증상평가척도(Scale for the for the Assessment of Positive Symptoms ; 이하 SAPS), 벡우울증척도(Beck Depression Inventory ; 이하 BDI), 신체감각증폭척도(Somatosensory Amplication Scale ; 이하 SSAS)의 변화를 비교하였다. 각 환자들은 항정신병약물 치료를 포함한 입원 치료를 받았으며, 갑상선기능이 불안정했던 경우 4주 후에 갑상선호르몬의 정상화를 확인하였다. 결과 : 8주 뒤에 갑상선기능정상 군과 갑상선기능불안정 군에서 SANS, BDI, SSAS 변화 차이가 의미 있게 나타났다. 갑상선기능정상 군에서 갑상선기능불안정 군에 비해 척도 점수가 크게 낮아졌는데, SANS는 23.3%(F=57.0, p<0.01), BDI는 19.6%(F=12.9, p<0.01), 신체감각증폭척도는 16.2%(F=17.1, p<0.01) 더 변화가 컸다. SANS, BDI, SSAS 세 지표 간에 유의한 상관관계는 없었다. 결론 : 정신분열병 환자들에게서 갑상선기능이 음성증상, 우울감, 신체증상에 관련된 예후에 표지가 될 수 있을 것이다.

• 대한조현병학회지
• /
• 제19권1호
• /
• pp.10-16
• /
• 2016

Objectives : This article aims to describe the development of smartphone application for the case management of patients with schizophrenia. Methods : Gwangju Bukgu-Community Mental Health Center developed and launched a smartphone application (HYM) for cognitive-behavioral case management and symptom monitoring. The development of the application involved psychiatrists, nurses, social workers, psychologists, and software technicians from a software development company (Goosl Corp.). Results : The HYM application for clients includes six main modules including Thought record, Symptom record, Daily life record, Official notices, Communication, and Scales. The key module is the 'Thought Record' for self-directed cognitive-behavioral treatment (CBT). When the client writes and sends the self-CBT sheet to the case manager, the latter receives a notification and can provide feedback in real time. 'Communication' and 'Official notices' are useful for promoting communication between case managers and clients with schizophrenia. Ratings in 'Symptom record', 'Daily life record', and 'Scales' modules are stored in graphic or table form representing changes in them and shared with case managers. Conclusion : The interactive function of this application is the key characteristics that distinguishes it from other mobile self-treatment tools. This smartphone application may contribute to the development of a youth- and customer-friendly case management system for individuals with early psychosis.

• 대한조현병학회지
• /
• 제23권1호
• /
• pp.29-37
• /
• 2020

Objectives: This study aimed to investigate the characteristics of early maladaptive schemas and their associations with clinical symptoms in patients with schizophrenia. Methods: Forty-eight patients with schizophrenia, 49 patients with major depressive disorder, and 50 healthy controls completed the Young Schema Questionnaire and symptom measures including the Brief Psychiatric Rating Scale-Expanded (BPRS-E). Results: The schizophrenia group had significantly higher scores than the healthy controls and lower scores than the depression group in most schemas. Compared with healthy controls, the schizophrenia group exhibited higher scores in 10 schemas, i.e., mistrust, social isolation, failure, dependence, vulnerability to harm, enmeshment, insufficient self-control, subjugation, emotional inhibition, and negativity schemas (all p<0.001). Moreover, vulnerability to harm, enmeshment, subjugation, and negativity schemas were correlated with total scores of the BPRS-E (0.37≤r≤0.43, all p<0.05). Regarding the five BPRS domains, emotional deprivation schema showed significant relationships with negative (r=0.50, p=0.005) and disorganization (r=0.39, p=0.033) symptoms, while no schemas showed correlations with positive symptoms. Conclusion: These results suggest that most schemas in patients with schizophrenia pertain to impaired autonomy and performance as well as disconnection and rejection domains and may improve our understanding and the treatment of schizophrenia from a perspective of schema therapy focused on these domains.

• 생물정신의학
• /
• 제28권2호
• /
• pp.70-77
• /
• 2021

Objectives Our study aimed to present the distinctive correlates of formal thought disorder in patients with schizophrenia, using the Clinical Language Disorder Rating Scale (CLANG). Methods We compared clinical characteristics between schizophrenia patients with (n = 84) and without (n = 82) formal thought disorder. Psychometric scales including the CLANG, the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale (YMRS), the Calgery Depression Scale for Schizophrenia (CDSS) and the Word Fluency Test (WFT) were used. Results After adjusting the effects of age, sex and total scores on the BPRS, YMRS and WFT, the subjects with disorganized speech presented significantly higher score on the abnormal syntax (p = 0.009), lack of semantic association (p = 0.005), discourse failure (p < 0.0001), pragmatics disorder (p = 0.001), dysarthria (p < 0.0001), and paraphasic error (p = 0.005) items than those without formal thought disorder. With defining the mentioned item scores as covariates, binary logistic regression model predicted that discourse failure (adjusted odds ratio [aOR] = 5.88, p < 0.0001) and pragmatics disorder (aOR = 2.17, p = 0.04) were distinctive correlates of formal thought disorder in patients with schizophrenia. Conclusions This study conducted Clinician Rated Dimensions of Psychosis Symptom Severity (CRDPSS) and CLANG scales on 166 hospitalized schizophrenia patients to explore the sub-items of the CLANG scale independently related to formal thought disorders in schizophrenia patients. Discourse failure and pragmatics disorder might be used as the distinctive indexes for formal thought disorder in patients with schizophrenia.

• 정신신체의학
• /
• 제13권1호
• /
• pp.32-40
• /
• 2005

연구목적 : 이 연구는 정신분열병 입원환자를 대상으로 감정표현 불능증과 임상변인 및 정신분열병의 연관 관계를 조사하고자 시행되었다. 방법: 두 대학병원 정신과 입원 시설에서 1년간 연속적인 수집을 통해 58명의 성인 정신분열병 환자가 이 연구에 참여하였다. 환자들에게 감정표현 불능증 척도(Toronto Alexithymia Scale, TAS), 양성 및 음성 증상척도(Positive and Negative Symptom Scale, PANSS), 간이정신진단검사(Symptom Checklist-90-Revised, SCL-90-R)를 시행하였다. 결과: 그 결과 TAS 총점은 SCL-90-R의 모든 하위 척도와 정적 상관 관계를 보였으며, 기존의 연구 결과와는 달리 PANSS의 양성증상, 음성증상, 일반 정신병리 척도 점수와는 유의한 상관이 없었다. 또한 '주관적 감각과 감정 경험의 혼동' 요인과 '감정 표현의 곤란' 요인은 SCL의 증상 척도와 유의하게 정적 상관하였으나, '공상의 빈곤'은 일부 하위척도와 부정 상관, '외부 지향적 사고'는 상관관계가 없었다. 다중회귀분석 결과는 SCL-90-R의 전체심도지수(GSI)가 감정표현 불능증의 28.2%를 설명하는 것으로 나타났다. 결론: 이 결과 및 객관적, 주관적 검사의 소견의 차이는 정신분열병의 감정표현 불능증이 두 가지 구성체, 즉 '감정 표현과 소통의 장애(상태적 요인)'과 '외부 지향적 사고(특성적 요인)'로 구성됨을 시사한다. 향후 정신분열병 환자를 대상으로 한 TAS의 구성 타당도 연구가 필요하다.

• 한국임상약학회지
• /
• 제11권2호
• /
• pp.89-96
• /
• 2001

Ziprasidone is equally effective as haloperidol in treating schizophrenia with fewer side effects and drug interactions. Ziprasidone is an atypical antipsychotic agent and works by blocking serotonin and dopamine receptors in the central nervous system, specifically 5-HT2A and D2 receptors. Low anticholinergic side-effects and low EPS would recommend the drug for use in the elderly. Ziprasidone inhibits reuptake of norepinephrine and serotonin at neurojunction sites in vitro, indicating a potential efficacy for depression and negative symptoms which often follow after exacerbation of schizophrenia. Patients with recent acute myocardial infarction and uncompensated heart failure are contraindicated to the drug due to a possibility of QT prolongation. Although ziprasidone is metabolized by cytochrome P450 3A4, there is no significant drug interaction with the drugs that induce or inhibit the isoenzyme. Ziprasidone is safe with coadministration of lithium and there has been no significant drug interaction reported with oral birth control pills.

• Journal of Yeungnam Medical Science
• /
• 제10권2호
• /
• pp.544-549
• /
• 1993

기질적 정신장애라 함은 뇌세포 기능의 장애로 인한 지남력 장애, 기억력 장애, 인격 기능 및 판단력의 장애와 정서의 천박성으로 특징지어지는 증상군으로 알려져왔다. 이에 본 저자들은 환자가 사회적 고립, 무의욕, 무감동, 사고의 빈약 등의 특징적인 정신분열증 음성증상소견을 주소로 입원하였으나 정밀한 검사를 한 결과 양측 전두엽의 위축으로 인한 기질성 정신장애로 밝혀진 환자를 경험하였기에 그의 임상증상을 문헌고찰과 함께 보고하는 바이다.

• 생물정신의학
• /
• 제18권4호
• /
• pp.225-231
• /
• 2011

Objectives Atypical antipsychotics show better treatment efficacy, safety and tolerability than typical antipsychotics. Among the adverse events observed during treatment with antipsychotics, extrapyramidal syndrome (EPS) and negative symptoms has been greatly reduced. But still, weight gain is receiving growing attention. The aim of this study was to investigate the association between therapeutic response to atypical antipsychotics and weight gain in admission status. Methods The study was conducted for Korean inpatients with schizophrenia in a university hospital in Seoul, between Jan 2006 and Dec 2010. Data was collected by reviewing the medical record of 39 consecutively hospitalized patients with Schizophrenia (DSM-IV) at a university hospital. Positive and Negative Symptom Scale (PANSS), Body Mass Index (BMI) and body weights were measured. Results No significant difference was observed for sex, age, illness onset age, family history of schizophrenia, numbers of hospitalization before treatment, educational years, marriage status, occupational status and subtype of schizophrenia between weight gainers and non-weight gainers. Regarding treatment response to atypical antipsychotics, weight gainers show significantly more PANSS decrease than non-weight gainers during admission period. Conclusions Our findings suggest that it appears to be more likely to respond to atypical antipsychotics in weight gainers than non-weight gainers (that weght gainers appear to be more likely to respond to atypical antipsychotics than non-weight gainers). These results show that the antipsychotic-induced body weight gain is associated with therapeutic response of antipsychotics in Korean inpatients with schizophrenia.

• 동의신경정신과학회지
• /
• 제18권3호
• /
• pp.209-224
• /
• 2007

Metabolic syndrome consists of several risk factors of metabolic origin like elevated blood pressure, abdominal obesity, elevated triglyceride concentrations, decreased HDL-cholesterol concentrations, and elevated fasting glucose. It appear to directly increase the development of atherosclerotic cardiovascular diseases which leading to cardiovascular diseases in later life. This 39 years female patient was diagnosed schizophrenia at the age of 17. but she didn't take reasonable treatments. during 20 years, she stayed in home and lived unsuited life with her family. As a result she gains heavy weight and centeral obesity, diabetic mellitus and hypertention, and developed cerevral vascular accident twice. This patient was treated with herb medication, acupuncture, western medication, psychotherapy primarily in focusing of pre-illness state(未病) as well as the stagnation of phelm. During 140 days of treatment from admission, before 2nd attack tbe patient showed improvement of Lt. hemiparesis but after second attack improved a little. And symptom of schizophrenia improved considerably. Also diet habit changed.

• 대한조현병학회지
• /
• 제22권2호
• /
• pp.21-33
• /
• 2019

Objectives: The current study covers a secondary revision of the guidelines for the pharmacotherapy of schizophrenia issued by the Korean Medication Algorithm for Schizophrenia (KMAP-SCZ) 2001, specifically for co-existing symptoms and antipsychotics-related side-effects in schizophrenia patients. Methods: An expert consensus regarding the strategies of pharmacotherapy for positive symptoms of schizophrenia, co-existing symptoms of schizophrenia, and side-effect of antipsychotics in patients with schizophrenia was retrieved by responses obtained using a 30-item questionnaire. Results: For the co-existing symptoms, agitation could be treated with oral or intramuscular injection of benzodiazepine or antipsychotics; depressive symptoms with atypical antipsychotics and adjunctive use of antidepressant; obsessive-compulsive symptoms with selective serotonin reuptake inhibitors and antipsychotics other than clozapine and olanzapine; negative symptoms with atypical antipsychotics or antidepressants; higher risk of suicide with clozapine; comorbid substance abuse with use of naltrexone or bupropion/varenicline, respectively. For the antipsychotics-related side effects, anticholinergics (extrapyramidal symptom), propranolol and benzodiazepine (akathisia), topiramate or metformin (weight gain), change of antipsychotics to aripiprazole (hyperprolactinemia and prolonged QTc) or clozapine (tardive dyskinesia) could be used. Conclusion: Updated pharmacotherapy strategies for co-existing symptoms and antipsychotics-related side effects in schizophrenia patients as presented in KMAP-SCZ 2019 could help effective clinical decision making of psychiatrists as a preferable option.